I-Mab (NASDAQ:IMAB) Rating Increased to Strong-Buy at Brookline Capital Management

I-Mab (NASDAQ:IMAB) was upgraded by Brookline Capital Management to a “strong-buy” rating in a research note issued on Thursday,Zacks.com reports.

Separately, HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of I-Mab in a research report on Friday, November 15th.

I-Mab Trading Up 2.9 %

Shares of IMAB stock opened at $0.93 on Thursday. The stock has a 50 day moving average of $0.99 and a two-hundred day moving average of $1.08. I-Mab has a 12 month low of $0.84 and a 12 month high of $2.00.

Institutional Investors Weigh In On I-Mab

Several hedge funds and other institutional investors have recently made changes to their positions in IMAB. XTX Topco Ltd grew its stake in shares of I-Mab by 140.8% during the third quarter. XTX Topco Ltd now owns 43,039 shares of the company’s stock worth $53,000 after purchasing an additional 25,163 shares during the period. Millennium Management LLC lifted its holdings in I-Mab by 763.1% during the fourth quarter. Millennium Management LLC now owns 97,749 shares of the company’s stock worth $83,000 after acquiring an additional 86,424 shares in the last quarter. BNP Paribas Financial Markets bought a new position in I-Mab during the fourth quarter worth about $93,000. Caligan Partners LP lifted its holdings in I-Mab by 3.7% during the third quarter. Caligan Partners LP now owns 3,499,330 shares of the company’s stock worth $4,339,000 after acquiring an additional 124,539 shares in the last quarter. Finally, Cantor Fitzgerald L. P. bought a new position in I-Mab during the fourth quarter worth about $119,000. 38.38% of the stock is owned by institutional investors and hedge funds.

I-Mab Company Profile

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.